Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK and Safety of Epetraborole in Renal Impairment
NCT05283746Phase 1Completed
- Sponsor
- AN2 Therapeutics, Inc.
- Start
- Feb 2022
- Primary completion
- Jun 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of epetraborole in Mycobacterium avium complex lung disease and nontuberculous mycobacteria infection (5 arms), sponsored by AN2 Therapeutics, Inc. Primary endpoints: Maximum Plasma Concentration at Day 8, Area Under the Plasma Concentration Versus Time Curve from Time 0 to Last Time Point at Day 8 and 10 more. Started Feb 2022; status: completed.
02
Drugs
epetraborole
03
Conditions
Mycobacterium avium complex lung diseasenontuberculous mycobacteria infection
Beyond the preview
Go deeper on NCT05283746.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05283746.